7 Best Peptides for Chronic Fatigue Syndrome (ME/CFS)

What to Know Before Choosing a Peptide for ME/CFS

ME/CFS is not a single disease with a single mechanism. Depending on the person, the dominant drivers might be mitochondrial dysfunction, immune dysregulation, gut-driven neuroinflammation, HPA axis problems, or some combination of all four. That complexity is why the peptide conversation around ME/CFS is broader and more fragmented than for most other goals: people are reaching for different compounds because they are trying to address genuinely different underlying problems.

A compound earns a place on this list because people use it for ME/CFS, or are actively discussing using it. FDA-approved, telemedicine-prescribed, and research-only compounds are all eligible. Evidence strength is stated honestly inside each entry rather than used as a filter for inclusion. This is especially relevant for ME/CFS, where no peptide has completed a human clinical trial specifically for this condition. The honest framing for this entire field is mechanistically promising compounds, significant preclinical interest, and a community of patients running real-world protocols because conventional treatment options remain so limited.

The entries below are numbered by how prominently each compound appears in the research literature and in real-world ME/CFS community use. That ordering reflects depth of discussion, not a verdict that compound one is better than compound seven for you. ME/CFS presents differently in different people, and matching the right compound or combination to a specific symptom profile is exactly the kind of personalized work that belongs in a structured plan rather than a general guide.

1. SS-31: The Most Prominently Discussed Option in Patient Communities

SS-31, also known as elamipretide or MTP-131, is a tetrapeptide that works directly inside the mitochondria by stabilizing cardiolipin, a phospholipid that sits on the inner mitochondrial membrane and is critical to the structure and function of the electron transport chain. Think of cardiolipin as the scaffolding that holds the cell's power-generation machinery in the right shape. When cardiolipin becomes damaged or disorganized, which happens under conditions of oxidative stress and chronic illness, the efficiency of ATP production drops sharply. SS-31 addresses this at the source by reducing mitochondrial reactive oxygen species, restoring ATP synthase function, and improving the physical structure of the mitochondrial cristae, the inner folds where most energy production actually happens.

For ME/CFS, the relevance is direct. The condition is strongly associated with impaired mitochondrial function and reduced ATP output, which is widely considered central to the post-exertional malaise and profound fatigue that define the disease. SS-31 is the compound most frequently cited across ME/CFS patient communities, generating accounts that no other peptide on this list comes close to matching. User-reported experiences include roughly 50 percent improvement in cognitive function, returning to tasks that had been impossible for months or years, and what some describe as experiencing meaningful energy for the first time in years, particularly when SS-31 is paired with NAD+.

No human clinical trial has been published for SS-31 in ME/CFS specifically. It has been studied in clinical trials for heart failure and Barth syndrome, both involving impaired mitochondrial function, but those results do not translate directly to ME/CFS claims. What exists for this condition is entirely user-reported, and the community reports are genuinely mixed: alongside the positive accounts are reports of paradoxical fatigue after injection, palpitations, insomnia, and worsening of autonomic symptoms even at very low amounts. The variability is wide enough that SS-31 appears to help some people significantly and aggravate symptoms in others. That is the honest picture, and it needs to be weighed carefully by anyone considering it.

2. MOTS-c: The Mitochondrial Peptide with the Strongest Mechanistic Fit

MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA-c, which is a way of saying it is a peptide expressed by a gene inside the mitochondria themselves rather than the cell nucleus. It acts as a retrograde signal, a message the mitochondria send to the nucleus to regulate how the whole cell handles energy. In people with ME/CFS, published research has confirmed reduced MOTS-c expression alongside measurable mitochondrial irregularities, which makes it one of the few compounds where a specific, documented biological deficit has been identified in the population that might benefit from supplementing it.

The mechanism runs through what researchers call the Folate-AICAR-AMPK pathway. AMPK is an enzyme sometimes described as the body's energy-sensing switch: when activated, it shifts cells from energy-storing mode into energy-producing mode. MOTS-c activates AMPK and, downstream, a protein called PGC-1alpha, the master regulator of mitochondrial production in skeletal muscle. The downstream effects include increased GLUT4 transporters that pull glucose into muscle cells more efficiently, higher NAD+ levels, and the growth of new mitochondria through a process called mitochondrial biogenesis. That last effect is what makes MOTS-c particularly relevant to the exercise intolerance and post-exertional malaise that are the hallmarks of ME/CFS.

The evidence is preclinical only. No human clinical trial has been published for MOTS-c in ME/CFS as of 2026. A 2025 research framework has described MOTS-c as a potential disease-modifying therapy for ME/CFS based on this mechanistic fit, and it is being discussed in the research literature as a near-term candidate for clinical trial development. Community use remains limited and outcomes are variable: some users in ME/CFS protocols report modest benefit when cycling MOTS-c, while others report that it initially worsened their PEM. The current state is mechanistically compelling, experimentally unvalidated in humans, and approached cautiously by community members who have tried it.

3. Thymosin Alpha-1: For Immune Dysregulation and T-Cell Exhaustion

Thymosin Alpha-1 is an immune-modulating peptide derived from thymosin fraction 5, a protein fraction originally isolated from thymus tissue. It has international regulatory acceptance, used in some countries to support immune function in chronic hepatitis and as an adjunct in cancer immunotherapy, though it is not FDA-approved for ME/CFS or for any indication in the United States at this time.

Its relevance to ME/CFS lies in the immune pathology that characterizes the disease. ME/CFS patients consistently show markers of T-cell exhaustion, including elevated PD-1 and Tim-3 expression, alongside reduced natural killer cell cytotoxicity and dysfunction in regulatory T-cells. These are not peripheral features; they are central to why the immune system in ME/CFS behaves the way it does, and they are the specific targets Thymosin Alpha-1 is designed to address. By restoring regulatory T-cell function, reducing the markers of T-cell exhaustion, and boosting natural killer cell activity, it theoretically targets the immune layer of ME/CFS rather than the mitochondrial one.

The FDA has reviewed data on Thymosin Alpha-1 and found no published evidence from clinical studies specifically in ME/CFS patients. Its international use is real and established, but for other immune conditions, not this one. Community use in ME/CFS is present: it appears frequently in combination protocols alongside BPC-157 and TB-500, with users reporting reduced inflammatory symptoms and improved immune resilience over time. That use is anecdotal, without a clinical measurement framework behind it. The honest description of the evidence for Thymosin Alpha-1 specifically in ME/CFS is: the immune rationale is strong, but human trial data for this indication does not exist.

4. BPC-157: For Gut-Driven Inflammation and the Brain Fog Connection

BPC-157, or Body Protection Compound-157, is a synthetic peptide derived from a protein found in human gastric juice. It is one of the most widely used peptides across multiple goals, primarily for its effects on tissue repair, wound healing, and gut integrity. In the ME/CFS context, its relevance comes from a specific feature of the disease: many people with ME/CFS have increased intestinal permeability, sometimes called leaky gut, which allows bacterial endotoxins called lipopolysaccharides to enter systemic circulation and drive neuroinflammation. That gut-to-brain pathway is now considered one of the contributing mechanisms behind the brain fog and CNS symptoms in ME/CFS.

BPC-157 has been studied in preclinical models for its ability to tighten intestinal tight junctions, specifically a protein called ZO-1 that acts like a seal between the cells of the gut lining. When ZO-1 function is restored, less of the endotoxin burden crosses into circulation, which reduces the downstream inflammatory signaling that reaches the brain. It also promotes blood vessel growth and local tissue healing in the gut mucosa. The evidence comes from animal models and in vitro studies, not human trials, and no clinical trial data exists for BPC-157 in ME/CFS specifically as of 2026.

Community reports from ME/CFS and Long COVID users describe BPC-157 resolving persistent gastrointestinal symptoms like chronic gastritis and diarrhea that had accompanied their fatigue, and some users describe it contributing to broader symptom improvement as part of multi-peptide protocols. It is rarely cited as addressing the core fatigue directly, but as clearing one of the contributing layers underneath it. Injection site reactions including pain and localized swelling are the most commonly reported side effects. It is often used in cycling protocols alongside TB-500 and sometimes with Thymosin Alpha-1.

5. NAD+: The Metabolic Foundation That Connects the Other Compounds

NAD+, nicotinamide adenine dinucleotide, is not a traditional peptide. It is a coenzyme, a small molecule that sits at the center of cellular energy metabolism and participates in hundreds of enzymatic reactions. It earns a place in this guide because it appears constantly in ME/CFS protocols, typically alongside the peptides listed here, and because the biological rationale for its relevance is grounded in the documented energy deficits of the disease. ME/CFS involves impaired NAD+ metabolism as part of its broader mitochondrial dysfunction: the Krebs cycle and the electron transport chain both depend on NAD+ as an essential cofactor, and when NAD+ is depleted, ATP production drops.

The connection to the other compounds is direct. MOTS-c's mechanism includes increasing cellular NAD+ levels as part of its downstream effect on mitochondrial biogenesis, meaning NAD+ is both a parallel intervention and a natural complement to mitochondrial peptide protocols. The most consistently positive community reports from ME/CFS patients tend to come from pairing SS-31 with NAD+: the mitochondrial membrane stabilization from SS-31 alongside the NAD+ repletion that the energy-generating machinery depends on.

NAD+ is available in several forms, from oral precursors like NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) that raise systemic NAD+ levels, to intravenous NAD+ delivered through integrative medicine clinics. The oral precursors are widely available as dietary supplements and are generally well tolerated. IV administration can cause flushing and nausea during infusion. No formal clinical trial data exists for NAD+ supplementation specifically in ME/CFS, but its use in integrative and functional medicine protocols for this condition is widespread, and the metabolic rationale is grounded in the documented energy deficits of the disease.

6. VIP: For Neuroinflammation and Autonomic Dysfunction

Vasoactive Intestinal Peptide, known as VIP, is a 28-amino acid neuropeptide produced naturally in the gut, nervous system, and immune cells. It has broad anti-inflammatory and autonomic regulatory effects, acting on receptors called VPAC1 and VPAC2 throughout the brain and body. In ME/CFS, two of the most debilitating features beyond the fatigue itself are neuroinflammation and autonomic dysfunction, which includes orthostatic intolerance, the inability to stand or sit upright without dizziness, palpitations, or near-fainting. VIP targets both.

Its anti-inflammatory action works by reducing pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-12, and by promoting the differentiation of regulatory T-cells while suppressing the Th1 and Th17 immune responses that drive inflammatory damage. Its autonomic effects come from direct modulation of both sympathetic and parasympathetic signaling, and its vasodilatory properties improve tissue perfusion in ways that could support energy delivery to poorly-perfused tissues. Some practitioners who treat Chronic Inflammatory Response Syndrome, a condition that overlaps with a subset of ME/CFS cases, particularly those with biotoxin or mold illness history, have incorporated VIP into multi-step protocols.

No human clinical trial data has been published for VIP specifically in ME/CFS. Its use in the ME/CFS community is narrower than the other compounds here, showing up primarily in the CIRS-overlap population and through functional medicine practitioners who prescribe it as a compounded nasal spray. Anecdotal reports from that population describe reduced inflammatory burden and improved cognitive function. One meaningful caution: because VIP suppresses certain immune responses, it is generally avoided in people with active infections, which is a relevant consideration given that immune activation is often present in ME/CFS presentations.

7. Selank: For HPA Axis Dysregulation and Cognitive Fog

Selank is a synthetic heptapeptide developed in Russia, where it has been studied and used in clinical contexts for anxiety and stress-related conditions. In the ME/CFS picture, it addresses a specific pathological thread that the other compounds on this list do not target directly: HPA axis dysregulation and the autonomic hyperreactivity that compounds cognitive symptoms. Many people with ME/CFS experience abnormal cortisol signaling, heightened anxiety, and a nervous system that treats mild exertion as a threat, driving post-exertional symptoms through that stress-response loop. Selank works as a positive allosteric modulator of GABA-A receptors, enhancing the calming effect of the brain's primary inhibitory neurotransmitter, and it stabilizes enkephalins, small peptides involved in pain and stress regulation.

Preclinical research using chronic unpredictable stress models has shown Selank reducing anxiety markers and restoring glucocorticoid receptor responsiveness, which is the biological mechanism through which cortisol signaling can normalize. In ME/CFS, correcting that receptor response could address the abnormal stress-response signaling that underlies some of the autonomic dysfunction and cognitive symptoms. Western clinical trial data is limited: almost all formal research on Selank has been conducted in Russia, with very little replicated in Western peer-reviewed journals.

What exists for ME/CFS specifically is community-reported, with users describing reduced brain fog and lower baseline anxiety as the primary effects. The evidence here is experiential rather than clinical for ME/CFS purposes, and the regulatory status in the US is research-chemical. Selank is not FDA-approved for any indication and is not available through standard compounding channels in the United States. It is typically encountered as a nasal spray in community protocols, which is its primary studied delivery route.

How These Peptides Compare

Frequently Asked Questions

Is any peptide FDA-approved specifically for ME/CFS?

No peptide is FDA-approved for ME/CFS treatment as of 2026. The FDA has not approved any pharmacological cure for ME/CFS, and the agency has explicitly stated it found no data supporting peptide-based treatments for this condition in its reviews. Current management remains symptom-focused, which is the context in which the research-only and off-label compounds in this guide are being explored by patients and practitioners.

Do any of these compounds have human clinical trial data for ME/CFS?

None of the compounds in this guide have completed a human clinical trial specifically for ME/CFS. SS-31 has been studied in clinical trials for other mitochondrial conditions, and Thymosin Alpha-1 has international regulatory acceptance for other immune conditions, but neither has been formally tested in ME/CFS patients in a controlled study. The field is operating almost entirely on mechanistic rationale and user-reported experience, which is precisely why stating the evidence plainly matters here.

Why does post-exertional malaise make peptide protocols more complicated for ME/CFS?

Post-exertional malaise, the worsening of symptoms that follows even mild physical or cognitive effort, means that some interventions tolerated by a generally fatigued person can trigger a significant crash in someone with ME/CFS. Community reports on several compounds in this guide, particularly SS-31 and MOTS-c, include accounts of initial PEM worsening or paradoxical fatigue after starting. That variability makes careful, low-and-slow approaches and close monitoring more important for this population than for most other goals.

Can these compounds be used together?

Combination protocols are common in ME/CFS communities, with frequently reported pairings including SS-31 with NAD+, BPC-157 with TB-500, and Thymosin Alpha-1 as an add-on to both. The rationale for pairing SS-31 with NAD+ makes biological sense: mitochondrial membrane stabilization and NAD+ repletion address adjacent parts of the same energy production problem. No combination protocol for ME/CFS has been studied in a controlled trial, and combining compounds that each carry their own side effect profiles adds complexity that warrants guidance from a practitioner familiar with this condition.

Are any of these compounds available through a doctor or telehealth clinic?

Availability varies significantly by compound. VIP is available as a compounded nasal spray through some functional medicine practitioners. Thymosin Alpha-1 is available through some compounding pharmacies as an off-label therapy. NAD+ precursors are available over the counter as dietary supplements, and IV NAD+ is offered through some integrative medicine clinics. SS-31, MOTS-c, and Selank occupy a more uncertain regulatory position, generally accessible only as research chemicals rather than through standard medical compounding for this indication. The regulatory landscape for peptide compounding is evolving, and discussing current options with a knowledgeable practitioner is the most reliable path forward.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for Chronic Fatigue Syndrome (ME/CFS) in one place.